Novartis Investigative Site

Salamanca, Castille and León 37007

1 studies enrolling now · 24 studies all time

What they study most

Acute Leukemias, Acute Myeloid Leukemia (AML), Advanced Breast Cancer, Breast Cancer, Cytokine Storm (Covid-19), Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Graft-versus-host Disease (GVHD), Hematologic Neoplasms, Hormone Receptor Positive Breast Cancer, Immune Thrombocytopenic Purpura (ITP), Leukemia, Myelomonocytic, Chronic, Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

Studies at this site

• CAR-T Long Term Follow Up (LTFU) Study — Recruiting now
• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) — Stopped early
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments — Completed
• Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS — Stopped early
• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) — Completed
• A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP — Completed
• Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma — Completed
• Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. — Completed
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) — Completed
• Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer — Completed
• Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma — Completed
• Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm — Completed
• Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma — Completed
• Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma — Completed
• Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. — Completed
• Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) — Completed
• A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma — Completed
• A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) — Completed
• Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma — Completed
• Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator — Completed
• Study of Secukinumab With 2 mL Pre-filled Syringes — Completed
• Safety and Efficacy of BKM120 in Relapsed and Refractory NHL — Completed
• Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia — Completed